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Abstract
Purpose: This retrospective study was done to better understand the conditions for which
stereotactic radiosurgery (SRS) for glioblastoma may be efficacious.
Methods: Between 2000 and 2007, 33 patients with a pathological diagnosis of glioblastoma
received SRS with the Novalis® Shaped Beam Radiosurgery system. Eighteen patients (54%)
underwent salvage SRS for recurrence while 15 (45%) patients received upfront SRS following
standard fractionated RT for newly diagnosed glioblastoma.
Results: There were no RTOG grade >2 acute side effects. The median survival after SRS was 6.7
months (range 1.4 – 74.7). There was no significant difference in overall survival (from the time of
initial diagnosis) with respect to the timing of SRS (p = 0.2). There was significantly better
progression free survival in patients treated with SRS as consolidation versus at the time of
recurrence (p = 0.04). The majority of patients failed within or at the margin of the SRS treatment
volume (21/26 evaluable for recurrence).
Conclusion: SRS is well tolerated in the treatment of glioblastoma. As there was no difference in
survival whether SRS is delivered upfront or at recurrence, the treatment for each patient should
be individualized. Future studies are needed to identify patients most likely to respond to SRS.
Introduction
Glioblastoma is an aggressive primary brain tumor with
poor outcome. Fractionated radiation therapy is the pri-
mary adjuvant treatment following resection or biopsy
[1]. The addition of concurrent (with radiation) and adju-
vant temozolomide has recently been shown to signifi-
cantly improve survival in glioblastoma, and is now
considered to be standard of care following resection [2-
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4]. However, the inability to adequately locally control
disease, either upfront or at recurrence, continues to be a
major challenge for this highly infiltrative tumor.
There appears to be a dose response to radiotherapy for
glioblastoma up to about 60 Gy. In late 1970s, retrospec-
tive analyses of previous randomized trials by the Brain
Tumor Study Group established a dose-response between
50 – 60 Gy for glioblastoma [5]. Another randomized
study by Medical Research Council confirmed that there is
an improvement in median survival from 9 months to 12
months when adjuvant radiation dose was increased from
45 Gy to 60 Gy [6]. Several prospective dose escalation tri-
als, some utilizing hyperfractionation or accelerated frac-
tionation regimens have suggested a possible dose
response relationship for glioblastoma, though no rand-
omized trials have shown any survival benefit over stand-
ard fractionated 60 Gy [1,7-15]. The Radiation Therapy
Oncology Group (RTOG) conducted a phase III rand-
omized study (RTOG 93-05) for newly diagnosed gliob-
lastoma to assess whether the addition of upfront
stereotactic radiosurgery (SRS) improves patient outcome;
the results suggested that an SRS boost does not signifi-
cantly improve disease control or patient survival [16].
Regardless of the initial treatment, glioblastoma recur-
rences predominantly occur at the site of the initial tumor
[17-20]. For recurrent glioblastoma, the prognosis is usu-
ally grim. Repeat surgery when feasible and chemotherapy
are often used for salvage of recurrent glioblastoma. Re-
irradiation with standard fractionated radiotherapy is fea-
sible, particularly with modern radiation techniques, but
often considered risky because of the cumulative dose to
a large volume of normal brain structures [21]. SRS, by vir-
tue of its improved set-up accuracy, allows for a reduction
in the volume receiving the prescribed dose, and can
therefore be advantageous over standard radiotherapy.
The role of SRS in this setting has not been tested in a pro-
spective randomized study. Several retrospective series
have demonstrated a median survival on the order of 7–
11 months, albeit with a of selection bias favoring
patients who are amenable to SRS [22-30]. We undertook
this retrospective analysis to look at the SRS dosimetry
treated with Novalis Shaped Beam Radiosurgery, as well
as the outcome of all treated patients.
Clinical Materials and Methods
The University of Rochester has been treating intracranial
lesions with SRS since December 1992 and has been using
the Novalis Shaped Beam Surgery system with BrainLAB
planning software since 2000.
The charts of 33 patients with a pathological diagnosis of
glioblastoma (WHO grade IV) who underwent SRS treat-
ment between November 2000 and April 2007 were retro-
spectively reviewed. The study was approved by the
University of Rochester Research Subjects Review Board.
Patient Selection
Patients were selected to be amenable to SRS if their
enhancing lesions were <4 cm in size. The decision for a
patient to undergo SRS following fractionated radiother-
apy for newly diagnosed glioblastoma was at the discre-
tion of the treating physicians, including the radiation
oncologist, medical oncologist and the neurosurgeon. The
majority of patients who received upfront SRS were either
treated prior to the published result of RTOG-93-05 or as
part of an ongoing protocol in which SRS was allowed
[31]. The decision for patients to undergo salvage SRS was
also at the discretion of the treating physicians.
Radiosurgery Treatment
SRS was delivered with the Novalis linear accelerator
(BrainLAB A.G., Heimstetten, Germany), equipped with
micromultileaf collimators (MLC), using 6 MV photons.
The tungsten MLC leaves at the center of the field are 3
mm in thickness. A BrainLAB stereotactic head frame
(BrainLAB A.G., Heimstetten, Germany) was used for
immobilization during the computerized tomography
(CT) scan and during treatment. A Novalis localizer frame
(BrainLAB A.G., Heimstetten, Germany) was attached
during the CT scan. CT and magnetic resonance imaging
(MRI) scans were used to delineate the target and normal
structures. Lesion enhancement seen on the Gadolinium-
T1 weighted MRI images were defined as GTV. The GTV
was expanded by 0–1 mm to generate the PTV. BrainLAB
planning software (BrainLAB A.G., Heimstetten, Ger-
many) was used to generate a treatment plan. The pre-
scribed isocenter dose was generally 10–20 Gy,
extrapolating from the RTOG protocol 90-05 guidelines
in which prescribed dose was dependent upon target vol-
ume [32]. The maximum prescribed dose was based on
size of the lesion and the proximity of critical structures.
We generally did not prescribe the isocenter dose >20 Gy.
Generally, the ≥80% isodose line covered ≥99% of the
PTV. The dose constraints for critical structures were: brain
stem <10 Gy; optic chiasm and optic nerves <8 Gy; nor-
mal brain (brain minus GTV) <14 Gy. All patients
received 10 mg of intravenous decadron prior to their SRS
and were kept overnight in the hospital for observation.
Follow-up
Following SRS, all patients were followed at 6 weeks and
thereafter every 2–3 months. For each follow-up examina-
tion, every patient underwent a contrast enhanced MRI
scan and a neurological evaluation. MR-spectroscopy,
MRI perfusion and/or PET imaging were performed as
needed to help to distinguish radiation necrosis from
tumor progression.Radiation Oncology 2009, 4:11 http://www.ro-journal.com/content/4/1/11
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Statistical analysis
Both overall survival and progression free survival were
our endpoint analysis. Using the Kaplan-Meier method,
overall survival was calculated from two different time
points: from the initial diagnosis and from the time of
SRS. Progression free survival was calculated from the
time of SRS until tumor recurrence, tumor progression or
death, which ever occurred first. All statistical analysis was
performed using statistical software Stata 9.1.
Results
Patient Characteristics
The patient and tumor characteristics are shown in Table
1. All patients had a Karnofsky performance status of ≥70.
The median age at the time of diagnosis was 57.8 years
(range 33–81 years). All patients received external beam
radiation, delivered to a median dose of 60 Gy (range 50–
64 Gy) with 1.8 – 2 Gy per fraction. Six patients were
treated with accelerated radiation (64 Gy, 1.6 Gy twice
daily) as part of a University of Rochester pilot proto-
col[31] Sixteen patients (48%), received temozolomide
concurrently during their fractionated radiotherapy, 2
patients received other concurrent chemotherapy and 15
(45%) patients received no concurrent chemotherapy.
The majority of patients (85%) received adjuvant chemo-
therapy after radiation while 15% received no adjuvant
chemotherapy. Adjuvant chemotherapy included single
agent temozolomide or BCNU in most patients. In a few
patients, other drugs, such as irinotecan or etoposide were
given in combination with BCNU or temozolomide.
A total of 18 patients underwent SRS at recurrence, 14
underwent SRS upfront as a consolidation and 1 patient
underwent SRS upfront as consolidation as well as at the
time of recurrence (12 months after the first SRS). The lat-
ter patient, for the purpose of data analysis, was included
in the group of patients undergoing upfront consolidative
SRS. Another patient received two salvage SRS procedures,
to the same location, for two chronologically separate
recurrences (8 months apart). In the 18 patients treated
for recurrence, the median interval from diagnosis to SRS
was 12.1 months (4.1 – 44.4); while in the other 15
patients it was 1.3 months (0.4 – 7.6). For patients who
received SRS at recurrence, the median interval from the
fractionated to the SRS was 9.1 months (range 1.8 – 40.2
months).
Table 2 summarizes the SRS dosimetric analysis. The
median dose at the isocenter was 14 Gy. The median and
maximum volume for consolidative and salvage SRS were
not significantly different (p = 0.2)
One patient who received 6.4 Gy at the isocenter under-
went SRS following fractionated radiotherapy for tumor
progression and worsening neurological symptoms. The
lesion was located in the left parietal lobe close to the
motor strip and had a cystic component as well as an
enhancing component of the lesion. The entire area was
treated using 2 isocenters. Given the patient's worsening
neurological symptoms, and close proximity of the motor
strip, he was treated with an unusually low dose.
Toxicity
The RTOG toxicity criteria were used. There was no grade
>2 acute toxicity. One patient developed grade 4 late-tox-
icity. This patient was initially treated with accelerated
radiotherapy (64 Gy in twice-daily 1.6 Gy fractions) with
concurrent temozolomide, followed by an SRS boost and
adjuvant temozolomide. His post-SRS MRI scans at 2 and
4 months showed enlarging tumor with altered enhance-
ment and decreased blood perfusion; magnetic resonance
spectroscopy revealed a largely lipid-lactate peak and
mildly elevated choline-creatinine ratio at the margin.
Ultimately, he underwent a second craniotomy 5 months
after his SRS. The pathology revealed 80% necrotic tumor,
with some viable tissue. Among the viable component,
small areas of fibrosis, blood pigment and macrophages
were seen along with gemistocytic and ganglionic type of
cells. The p-53 was rare and there was minimal Ki-67
activity. His post-operative MRI showed no residual
necrotic tumor but post-surgical changes. Unfortunately,
he developed wound complications and is currently
recovering from his third craniotomy.
There are 4 patients who are long-term (>3 years) survi-
vors from glioblastoma, 2 of whom have long-term fol-
low-up after SRS. One patient is alive at 76 months from
the diagnosis of glioblastoma in the left temporal lobe,
and 75 months from SRS. He is decadron dependent and
suffers from neurocognitive decline, slurred speech and
expressive aphasia. He was treated with upfront SRS (15
Gy) following 63 Gy of fractionated radiation; he also





Age ≤ 50 9 (27)
Age > 50 24 (73)
Extent of surgical resection
Gross total resection 8 (24)
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received a short course of etoposide and >3 years of temo-
zolomide.
A second long term survivor is alive at 50 months from
SRS and 76 months from the diagnosis. She suffers short-
term memory loss and psychosocial difficulty. She was
treated with fractionated radiotherapy (63 Gy) and con-
current temozolomide. At her first tumor recurrence, she
was treated with 9 cycles of BCNU & irinotecan. She suf-
fered a second, PET positive, recurrence 9 months later
and was treated with SRS (12 Gy). She also was given 28
months of high dose (80 mg) Tamoxifen. Another patient
died at 47 months from original diagnosis, and 13
months after SRS, as a result of neurocognitive decline,
with apparent local control of his tumor (based on MRI
follow-up). He suffered a total of 4 recurrences and was
treated quite aggressively with a salvage gross total resec-
tion, as well as two separate radiosurgeries at recurrence
(20 and 18 Gy at the isocenter, respectively). He also
received adjuvant chemotherapy with BCNU, thalido-
mide and temozolomide at recurrence. In these 3 patients,
it is difficult to ascribe the cause of the late treatment
effect, which may or may not be attributable to radiosur-
gery.
A fourth patient is alive at 6 months from SRS and 50
months from diagnosis with recurrent and progressive
disease. He was treated with radiation (59.4 Gy) with con-
current and adjuvant temozolomide. He suffered recur-
rence after 2 years and was treated with bevacizumab and
irinotecan initially followed by SRS (10 Gy).
Outcome
The median survival from the time of initial diagnosis was
16.9 months (4.5 – 76.2 months). The 1-year, 2-year and
3-year overall survival rates were 72%, 23% and 14%
respectively. Figure 1 depicts overall survival from the
time of diagnosis. There was no difference in survival
whether patients received SRS as consolidation or at recur-
rence (p = 0.4).
The median survival from the time of SRS was 6.7 months
(1.4 – 74.7 months). Figure 2 illustrates the survival curve
from the time of SRS. The patients who received up-front
Table 2: Radiation treatment parameters
Median Minimum Maximum
Dose @ isocenter (Gy)*
All patients 14 6* 20
Upfront SRS 13 6* 20
SRS at recurrence 15 9 20
Peripheral dose (%)
All patients 80 40 100
Upfront SRS 80 50 100
SRS at recurrence 80 40 90
Number of isocenters
All patients 21 7
Upfront SRS 1 1 3
SRS at recurrence 2 1 7
Number of beams/arcs
All patients 12 6 32
Upfront SRS 12 7 24
SRS at recurrence 12 6 32
GTV (ml)
All patients 9.2 0.2 85.4
Upfront SRS 13.2 1.5 85.4
SRS at recurrence 8.4 0.2 32.2
Upfront fractionated RT dose (all patients) 60 50 65
* because of worsening neurological symptoms, large treatment volume and critical location, one patient was prescribed an unusually low isocenter 
dose of 6 Gy.
Overall survival from the initial diagnosis Figure 1
Overall survival from the initial diagnosis.Radiation Oncology 2009, 4:11 http://www.ro-journal.com/content/4/1/11
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SRS had a median survival of 10.3 months compared to
5.3 months among those who received SRS at recurrence,
although this difference was not statistically significant on
univariate analysis (p = 0.1). Table 3 summarizes the
patient survival.
The median progression free survival from the time of SRS
was 4.3 months (1.3 – 74.7 months). On univariate anal-
ysis, patients who had SRS as consolidation had a signifi-
cantly better progression free survival compared to
patients who received SRS at the time of recurrence
(median progression free survival of 6 months vs. 3.4
months, respectively, p = 0.04) (Figure 3).
As part of out hypothesis-generating analysis, we looked
at various prognostic variables for overall survival, includ-
ing age, tumor location, type of surgery, use of concurrent
chemotherapy, and timing of SRS. Only temporal lobe
location was significantly better on univariate analysis (p
= 0.01).
Recurrence pattern prior to SRS
For patients (n = 18) who underwent SRS for recurrence,
all except one have information about their recurrence
pattern prior to the SRS. Nine patients (53%) failed within
the previously irradiated volume, while 3 patients (17%)
failed both within and at the margin of the previously irra-
diated volume. Three patients (17%) failed both outside
and within the irradiated volume. One patient (6%) failed
at the margin only and 1 patient (6%) failed only outside
the previously irradiated volume.
Recurrence pattern after SRS
Seven patients were unable to be evaluated for recurrence,
due to loss of follow-up (n = 3) or death prior to imaging
follow-up (n = 4). Three patients were locally controlled
at last follow-up, 3 of whom are alive at 74.7, 50.4 and 4
months after SRS, and 75.4, 50.4, 7.3 months after initial
diagnosis, respectively. Among the 23 patients who expe-
rienced recurrence, 21 (92%) recurred within the SRS field
or at the field margin, while 1 (8%) recurred outside of the
SRS field.
Salvage treatment
Information about salvage therapy at recurrence was avail-
able in 29 patients and is summarized in Table 4. Two
patients had SRS for subsequent recurrences and two
patients underwent surgical salvage prior to SRS. The
majority of patients received salvage chemotherapy.
Discussion
glioblastoma continues to be a challenging disease to
treat, with most patients succumbing to their disease in
the course of a few months to a few years. Since the late
1970s when adjuvant radiation was found to improve sur-
vival, very little progress has been made in further improv-
ing the survival. In 2005, the EORTC and NCIC conducted
a phase III trial, investigating temozolomide during and
after radiation [2]; this regimen yielded a modest but sig-
nificant improvement in survival for this aggressive
tumor, a small impact made almost after 25 years since
the report by Walker et al established that 60 Gy as the
most effective dose for glioblastoma from a pooled retro-
spective analysis [5].
The inability to control the tumor locally, with distant
brain metastases being far less common than local recur-
rence, led to the hypothesis that by increasing the radia-
tion dose, local control and survival may improve. SRS is
Overall survival from the time of stereotactic radiosurgery Figure 2
Overall survival from the time of stereotactic radio-
surgery.






Median time interval from diagnosis to SRS 1.3 12.1
Median survival from diagnosis 13.2 17.4 0.4
Median survival from SRS 10.3 5.3 0.1
Median progression free survival from SRS 6.0 3.4 0.04
M = months
SRS = stereotactic radiosurgeryRadiation Oncology 2009, 4:11 http://www.ro-journal.com/content/4/1/11
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one of the methods of dose escalation which had been
hypothesized to improve outcome [33,34]. The RTOG 93-
05 study randomized >200 patients with glioblastoma to
SRS boost in addition to 60 Gy fractionated radiation and
BCNU chemotherapy; no survival benefit was appreciated
with the addition of an SRS boost [16]. As size was a crite-
rion for eligibility for SRS boost, a subsequent analysis of
RTOG data found even by RPA stratification, SRS offers no
significant added advantage [35]. In an attempt to further
clarify the role of SRS in malignant glioma, Tsao M et al.
reviewed the literature and concluded that there is level I-
III evidence that the addition of an upfront SRS boost to
fractionated radiation and BCNU offers no benefit to sur-
vival, local control or quality of life in malignant glioma,
with a greater risk of toxicity [36]. Similar conclusions
were reached in an evidenced based review in this journal,
though the authors conclude that "selected patients may
benefit but the specific characteristics of this group have
yet to be identified" [1].
Because a high percentage of patients experience local
recurrence following standard therapy, salvage therapy is
often challenging. Resection, chemotherapy or radiation
are the various options which play an important role in
the management of recurrent disease [37,38]. Retrospec-
tive data, including matched pair analyses suggest that sal-
vage therapy prolongs progression free survival and
overall survival, albeit with a selection bias favoring those
patients undergoing salvage [39]. Since these tumors are
quite infiltrative, a second surgery is often not feasible.
Fractionated re-irradiation can be quite risky because a
larger volume of previously treated brain is enclosed
within the radiated volume. SRS, by virtue of rigid immo-
bilization, allows for minimal radiation dose exposure to
surrounding tissue. SRS is therefore well suited for
patients undergoing a second course of radiation, as the
normally accepted dose tolerances of normal structures
would otherwise likely need to be exceeded to ensure ade-
quate target coverage. In the RTOG 93-05 study, 19% of
patients randomized to the arm without upfront SRS
received SRS as salvage, 6% received fractionated radia-
tion and 35% underwent salvage surgery. In contrast, 6%
of patients randomized to the arm with upfront SRS
received SRS as salvage, 7% received fractionated radia-
tion and 33% underwent resection. Arguably, one can
conclude that the RTOG 93-05 study does not necessarily
show that SRS is not beneficial in patients with glioblast-
oma, but rather SRS can be delayed as part of salvage ther-
apy without a detriment in survival.
The data on salvage SRS for recurrent glioblastoma is
sparse and mostly retrospective making it difficult to
interpret. A few retrospective studies have examined SRS
with recurrent glioblastoma; these are summarized in the
Table 5. The median survival after SRS is on the order of
8–12 months. Late toxicity other than radiation necrosis
is uncommonly reported. Among those patients who
undergo a neurosurgical procedure for progression and/or
suspected radionecrosis, necrosis is admixed with viable
tumor cells in nearly all samples. Generally, radionecrosis
is reported in roughly 5–10% of cases,36,37 though most
patients develop radiographic evidence of necrosis [40].
The number of patients who are found to have pathologic
necrosis will obviously be impacted by the aggressiveness
of the neurosurgeon and the amenability of the tumor
and patient to surgical exploration and debulking. As a
consequence, the extent of radionecrosis after SRS is diffi-
cult to accurately quantify and characterize, but certainly
it is not prohibitive to treatment, particularly since tumor
progression is the primary means of death and dimin-
ished quality of life in most patients.
Progression free survival: upfront stereotactic radiosurgery  (SRS) versus SRS for recurrence Figure 3
Progression free survival: upfront stereotactic radio-
surgery (SRS) versus SRS for recurrence.
Table 4: Salvage therapy
Patients treated with upfront SRS, n = 15 Patients treated with SRS at recurrence, n = 18
Salvage after SRS Salvage prior to SRS Salvage after SRS
Surgery 1 2
Chemo 7 4 14
Radiation 1
2nd SRS 1 1Radiation Oncology 2009, 4:11 http://www.ro-journal.com/content/4/1/11
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In our study, the median survival following SRS was 6.7
months which is comparable with the most reported
series. The majority of the patients who received SRS as an
upfront boost were treated prior to the reported results of
RTOG 95-03. The median survival from the time of SRS
for the up-front SRS was slightly better (10.3 months)
compared to the patients who had SRS at recurrence (5.3
months). However, the median interval between the diag-
nosis and SRS was 1.3 months versus 12.1 months for
patients who had consolidative SRS and SRS at recurrence,
respectively. When we looked at the overall survival from
the time of diagnosis, there is no difference in these two
groups. Interestingly, we found significant improvement
in progression-free survival when SRS was added as a con-
solidative treatment. We did not analyze the quality of life
measure to see if delay in progression free survival is asso-
ciated with any improvement in quality of life.
We have two long term survivors over 6 years in each
group indicating it is not only the treatment but also the
tumor biology which is probably crucial. As we develop
greater understanding of tumor biology, we might be able
to identify a subset of patients who would require more
aggressive therapy compared to those who will do better
without any aggressive therapy [41,42]. A recent article by
Krex et al. suggested that patients who have hypermethyl-
ated MGMT protein are the long-term survivors [42]. Hegi
et al. reported from the EORTC randomized trial that
those patients who had methylated MGMT gene benefited
significantly better from temozolomide than the patients
who did not [43]. Most of the SRS literature pre-dates the
temozolomide era. Currently, whether more aggressive
initial local therapy, including SRS, will have more benefit
among patients receiving temozolomide, with or without
the methylated MGMT gene, is unknown.
In our series, there was no RTOG >grade 2 acute toxicity
seen. One patient developed grade 4 late toxicity and
underwent craniotomy for this. The pathology largely
showed necrosis (80%) with some viable tissue including
both fibrosis and tumor cells and minimal Ki-67 activity.
Among our 4 long-term survivors who lived over 4 years
since the diagnosis of their glioblastoma, three are still
alive. One patient died presumably from treatment
related toxicity. However, he received aggressive surgery,
multiple courses of radiation and prolonged chemother-
apy and all these factors might have contributed to the
toxicity rather than just radiation. The other patient who
is still alive after 6 years has grade 2 late toxicity.
Table 5: Summary or studies on the use of salvage stereotactic radiosurgery for recurrent glioblastoma
Institution (year) #rGB/# total Median dose [range] (Gy) Prescription MS (M) Late toxicity
Brigham & Women's Hosp. 
(1995) [22]
86/86 13 [6-20] 50–90% IDL
Median 80%
10 19 pathologic necrosis
1 CN palsy
U. Pittsburgh (1997) [23] 19/107 NR NR 30 1 symptomatic necrosis
12 pathologic necrosis 
(of 60 GB patients)
U. Minnesota (1999) [24] 27/46 17 [9-40] 30–90% IDL
Median 50%
7 8 pathologic necrosis
6 clinical necrosis
U. Wisconsin (1999) [25] NR/30 NR 50–80% IDL 7 NR
Cleveland Clinic (2000) [26] 23/23 15 [12-20] 50–80% IDL 10 1 pathologic necrosis
2 increased seizures
UCSF (2002) [27] 14/26 [~10–22] 50% IDL 10 Not assessable
UCSF (2002) [27] 39/54 [~12–18]
+ marimastat
25–30% IDL 9 Not assessable
U. Heidelberg (2005) [28] 32/32 15 [10-20] 80% IDL covers tumor 10 None
MDACC (2005) [29] 40/40 NR NR 11 8 pathologic necrosis
Henry Ford (2007) [30] 26/26 NR 18 Gy at margin 9 NR
Current series 18/33 15 [9-20] 80% IDL covers tumor 7 See text
Abbreviations: rGB = recurrent glioblastoma, GB = glioblastoma, SRS = stereotactic radiosurgery; IDL = isodose line. NR = not reported.Radiation Oncology 2009, 4:11 http://www.ro-journal.com/content/4/1/11
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In conclusion, SRS is generally a well tolerated treatment
both as a boost and as a salvage therapy. As there was no
difference in survival between the two groups, the deci-
sion of adding SRS to fractionated treatment should be
based on individual patient status and preference. In the
temozolomide era, the role of SRS needs to be better
defined by future studies.
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